Nippon Kayaku Co., Ltd. 4272
TSE · Japan · Process Industries
¥2,130.00+23.00 (+1.09%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Growth is driven by the increasing demand for advanced semiconductor solutions in electric vehicles and high-performance computing. Electric vehicles, with higher semiconductor content, are significantly driving the market due to applications in battery management, power electronics, and infotainment systems. Fan-out packaging shows promising growth, crucial for compact, high-performance semiconductors. Europe emerges as a key regional player, bolstered by initiatives like the European Chips Act
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement with Nippon Kayaku Co., Ltd. ("Nippon Kayaku") to advance GNX201-ADC, a next-generation antibody-drug conjugate (ADC) candidate for the treatment of solid tumors. Under the agreement, the two companies will jointly support preclinical development activities for GNX201-
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.